Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
President Trump also said he is "not looking for a partial deal" with Beijing, moving away from his suggestion last week that he would consider an "interim deal."Politicsread more
Progress on trade talks will determine how far market will move above new highs.Trader Talk with Bob Pisaniread more
"Sure, the trade war's taking its toll on business ... it's just not taking its toll where it was supposed to," Jim Cramer says.Mad Money with Jim Cramerread more
Joe Biden called on President Donald Trump Friday to release the transcript of a call with a foreign leader that is the subject of a whistleblower complaint. Biden described...Politicsread more
For investors taking a breather from the chaos in August, buckle up as the market is about go crazy again, Goldman Sachs warned.Marketsread more
Palantir Technologies is targeting a valuation of at least $26 billion in a private fundraising round, the first for the Peter Thiel-backed data analytics startup in four...Wall Streetread more
Michael Pack, a conservative filmmaker linked to Steve Bannon, saw at least $1.6 million in donations from his nonprofit sent into the coffers of his independent production...Politicsread more
The New England Patriots released Antonio Brown just 11 days after signing the wide receiver. The NFL Super Bowl champion team initially had kept him in the face of a rape...Sportsread more
Biotech start-up 10x Genomics surged as much as 49% in its market debut Thursday. The stock opened trading at $54 and rose as high as $58 per share midday before closing at $53.
The company, which provides scientists gene sequencing technologies to help cure chronic diseases like cancer and Alzheimer's, priced its 9 million shares Wednesday night at $39 per share, above the expected range of $31 and $35.
The stock is among the top 25 IPO debut performances year to date.
10x Genomics is backed by investors like Softbank, Fidelity and Meritech Capital partners, among others.
CEO and co-founder of Serge Saxonov told CNBC's "Squawk Alley" Thursday that demand for the company's services insulates 10x Genomics from typically unpredictable swings in public medical funding.
While other comparable genome sequencing companies like Illumina have taken a hit in recent months due to weakness in the direct-to-consumer market, Saxonov told CNBC's Morgan Brennan and Jon Fortt that those trends don't impact his long-term outlook for gene sequencing technology.
"Illumina had a little bump in the road perhaps, but the ultimate future is really, really promising and really big. When I look at the long term, which tends to be my outlook, I have no concerns at all," said Saxonov, who previously served as the director of research and development at 23andMe.